SER
Serina Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Serina Therapeutics, Inc.
Expected move
No implied move.
Next report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Linked news
Bull1
Bear2
No changes.
No changes.
| Manager | Value | % base | |
|---|---|---|---|
| Sio | $1.9M | 71.09% | 0.00% |
| Vanguardindex-like | $314,664 | 11.53% | +1.92% |
| Warren Averett | $130,934 | 4.80% | 0.00% |
| Geodeindex-like | $98,955 | 3.63% | −21.50% |
| Keel Point | $41,726 | 1.53% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Sio | $1.9M | 71.09% | 0.00% |
| Vanguardindex-like | $314,664 | 11.53% | +1.92% |
| Warren Averett | $130,934 | 4.80% | 0.00% |
| Geodeindex-like | $98,955 | 3.63% | −21.50% |
| Keel Point | $41,726 | 1.53% | 0.00% |
No peers for Serina Therapeutics, Inc. yet.
No peers for Serina Therapeutics, Inc. yet.
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 25 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Serina Therapeutics, Inc.
1.93
+0.04 · +2.12%
post 1.98 +2.59%
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.